Limelight Bio, Inc. is an emerging biotech company developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors to enable the treatment of debilitating inherited diseases that cannot be addressed by current technologies; such as those caused by mutations in large genes and autosomal dominant inheritance patterns.
